Clinical Trials Logo

Graft vs Host Disease clinical trials

View clinical trials related to Graft vs Host Disease.

Filter by:

NCT ID: NCT04976699 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

CATHY
Start date: January 5, 2021
Phase: Phase 3
Study type: Interventional

The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.

NCT ID: NCT04971551 Not yet recruiting - Clinical trials for Acute Graft-Versus-Host Disease

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Start date: September 2021
Phase: Phase 2
Study type: Interventional

This is an single-arm, Phase II multi-center study. The purpose of this study is to assess the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease.

NCT ID: NCT04958538 Recruiting - Clinical trials for Acute Graft Versus Host Disease

MTX and Steroid for III-IV aGVHD Treatment

Start date: April 21, 2021
Phase: Phase 2
Study type: Interventional

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

NCT ID: NCT04954573 Recruiting - Clinical trials for Sclerotic Graft-versus-host Disease (GVHD)

Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This is a prospective, intra-individual comparative study to evaluate the effectiveness of local-water filtered infrared-A (wIRA) irradiation (applied by Hydrosun® radiator 750 for radiation at the clinic, or Hydrosun® 575home for home treatment) in patients with morphea or sclerotic GVHD (Graft-versus-host Disease). The purpose of the study is to determine whether wIRA irradiation can reduce fibrotic skin alterations in circumscribed scleroderma (morphea) or chronic graft versus host disease. wIRA irradiation is applied for 30 minutes 3 times per week for 20 weeks to a diseased skin area and a lesional skin on contralateral body site remains untreated. A total of 22 patients (20 evaluable patients with an expected drop-out rate of 10%) are to be included in this study. Group A: 11 patients with plaque morphea Group B: 11 patients with sclerotic GVHD.

NCT ID: NCT04944043 Recruiting - Clinical trials for Chronic Graft Versus Host Disease

A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease

Start date: June 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and phase II for the extension study.

NCT ID: NCT04934670 Not yet recruiting - Clinical trials for Steroid-Refractory Acute Graft Versus Host Disease

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

2002
Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host Disease (SR-aGVHD). The primary hypothesis is that T-Guard treatment will improve the Day 28 complete response (CR) rate in patients with Grades III and IV SR-aGVHD compared to ruxolitinib.

NCT ID: NCT04930562 Recruiting - GVHD, Chronic Clinical Trials

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

NCT ID: NCT04926194 Active, not recruiting - Clinical trials for Myelodysplastic/Myeloproliferative Neoplasm

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

DSC-SR
Start date: March 11, 2021
Phase: Phase 2
Study type: Interventional

This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).

NCT ID: NCT04922736 Not yet recruiting - Clinical trials for Graft Vs Host Disease

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

Start date: June 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the degree of improvement seen patient reported outcomes after 30 sessions of UVA-1 therapy in treating systemic scleroderma, morphea, and sclerodermatous Graft-Versus-Host Disease. While patients have verbally reported improvement of their sclerosing skin disease with UVA-1, patient reported outcomes have not been rigorously studied. In sclerosing skin diseases where clinical change is difficult to measure, patient reported outcomes may offer a better way to study the impact of treatments like UVA-1. This will be a non-blinded, non-randomized prospective trial using UVA-1 phototherapy in patients with established sclerosing skin disease. Patients will report the severity of their condition using multiple patient reported outcomes and will also be analyzed using multiple clinical investigator assessments at the beginning and end of 30 treatment sessions.

NCT ID: NCT04910152 Not yet recruiting - Clinical trials for Acute Graft Versus Host Disease

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Start date: July 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side effect profile. PLX51107 may work better in treating steroid-refractory acute GVHD.